Creative Medical Technology Holdings Marks Milestone with ADAPT Trial
PHOENIX — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in clinical-stage biotechnology, has made a significant advancement in regenerative medicine by announcing the successful completion of patient enrollment in the FDA-cleared ADAPT clinical trial. This trial is centered around CELZ-201 (Olastrocel), a groundbreaking cell therapy targeting chronic lower back pain stemming from degenerative disc disease.
Positive Developments in Clinical Safety Milestones
The completion of enrollment is particularly noteworthy as it follows a favorable safety review by an independent Data Safety Monitoring Board (DSMB). The DSMB confirmed a promising safety profile for CELZ-201, reporting no significant adverse events, which has promoted the continuation and advancement of the trial.
Transition to the Next Phase of the ADAPT Program
With the enrollment phase concluded, Creative Medical Technology is poised to transition the ADAPT program into follow-up stages and comprehensive data analysis. Executives, clinical investigators, and partner organizations have expressed enthusiasm as they work toward what is envisioned as a transformational treatment approach for chronic back pain, a condition affecting over 16 million individuals in the U.S., with a multi-billion-dollar market filled with limited non-surgical solutions.
A Shift Toward Innovative Back Pain Treatments
Timothy Warbington, President and CEO, described this achievement as a defining moment for Creative Medical Technology. He emphasized that completing enrollment validates their operational capabilities and reflects a growing interest in CELZ-201 among both clinicians and patients. As they move into the next phase, there is a strong commitment to generating impactful clinical data that may revolutionize how chronic lower back pain is treated, steering away from surgery and the dependency on long-term opioid medications.
Understanding the ADAPT Trial's Objectives
The ADAPT trial (CELZ-201-ADAPT-202) is designed as a double-blind, placebo-controlled, randomized, and dose-escalation study to assess the safety, tolerability, and initial effectiveness of CELZ-201, administered through a minimally invasive ultrasound-guided intramuscular procedure. The structure of the study involves stringent safety measures including DSMB monitoring and adverse event tracking in accordance with regulatory standards.
Real Patient Data Drives Excitement
As Warbington stated, the trial's findings are rooted in reality, representing patients who experience true relief from their conditions. He reiterated that the ADAPT trial is structured to confirm previous research suggesting CELZ-201 could provide long-lasting, disease-modifying benefits in a medical landscape in dire need of innovation.
Addressing a Significant Market Need
Chronic lower back pain has long been recognized as a leading global cause of disability. Conventional management often leans heavily on surgical intervention, frequent steroid injections, or chronic opioid use. Unlike these options, CELZ-201 is characterized as an “off-the-shelf,” allogenic cell therapy. This approach ensures scalability, consistent results, and broad clinical applicability, distinguishing it from autologous therapies.
Leveraging Intellectual Property for Strategic Advantage
Creative Medical Technology's StemSpine® intellectual property portfolio supports both autologous and allogenic applications, enhancing the company’s strategic market position as it advances toward later clinical trial stages and potential commercialization opportunities.
Next Steps and Future Outlook
As the enrollment phase concludes, Creative Medical Technology has outlined several key actions for the upcoming months:
- Continuing regular DSMB reviews to ensure ongoing safety and efficacy.
- Progressing toward key safety and efficacy readouts.
- Exploring strategic paths for late-stage development and options for commercialization focused on opioid-dependent patients.
Management believes that the forthcoming milestones signify numerous value-creation opportunities for shareholders as CELZ progresses along its clinical roadmap.
Commitment to Excellence Moving Forward
Warbington underscored the company's commitment to a results-driven approach as they venture into this new phase. The team’s focus remains sharp on executing flawlessly, producing compelling data, and fully unlocking the potential benefits of CELZ-201 for both patients and investors.
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) is pioneering clinical-stage biotechnology focused on developing regenerative medicine therapies derived from adult and perinatal stem cell technologies. Their diverse pipeline includes innovative solutions across orthopedics, immunotherapy, endocrinology, urology, and gynecology, demonstrating a commitment to turning cutting-edge scientific advancements into accessible, transformative treatments for patients in need.
Frequently Asked Questions
1. What is the ADAPT trial about?
The ADAPT trial is designed to evaluate the safety and efficacy of CELZ-201, a cell therapy for chronic lower back pain.
2. What are the key milestones reached by Creative Medical Technology Holdings?
They recently completed patient enrollment in the ADAPT trial, marking a significant advancement in their clinical research.
3. How does CELZ-201 differ from traditional treatments?
CELZ-201 offers a non-surgical, allogenic cell therapy option that can potentially modify the disease instead of just alleviating symptoms.
4. What markets does Creative Medical Technology Holdings target?
The company targets a variety of markets, including orthopedics and pain management, focusing on conditions with high unmet medical needs.
5. How can CELZ-201 impact chronic back pain management?
CELZ-201 has the potential to provide durable relief and reduce dependence on opioids or invasive surgeries for chronic back pain patients.
